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During the last five decades, five pyridinium oximes were found to be worthy of use as antidotes against 
nerve agents in humans: pralidoxime, in a form of chloride or PAM-2 Cl and mesylate or P2S (against 
sarin, cyclosarin and VX), trimedoxime or TMB-4 and obidoxime or LüH-6 (both against tabun, sarin and 
VX), HI-6 (against sarin, soman, cyclosarin and VX) and HLö-7 (against all the five nerve agents).
In order to provide the auto-injector with the best and most potent acetylcholinesterase reactivator, the 
Defence Research and Development Canada (DRDC) received in the 1990s a core funding from the 
federal government’s CBRN research and Technology Initiative (CRTI). Its ultimate result should be three 
products: (1) 3-in-1 auto-injector (atropine, HI-6 dimethanesulphonate and avizafone, as anticonvulsant), 
(2) 2-in-1 auto-injector (atropine and HI-6 dimethanesulphonate) and (3) HI-6 dimethanesulphonate in a 
vial for administration by the medically trained personnel.
Previous experimental and clinical experience suggests that, among the oximes mentioned, only 
trimedoxime and obidoxime can be used for acetylcholinesterase reactivation and antidotal protection 
against most of the organophosphorus insecticides.
The search for an “omnipotent” oxime, effective in reactivation of AChE inhibited with both nerve agents 
and organophosphorus insecticides, is still ongoing.
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Atropine seemed to be the only antidote available 
for the treatment of poisoning with organophosphorus 
compounds (OPC) until 1951, when Jandorf made 
the first step towards the solution of this problem by 
showing that hydroxylamine could destroy OPCs in
vitro (1). These results inspired Wilson to try adding 
hydroxylamine to tetraethyl pyrophosphate (TEPP)-
inhibited acetylcholinesterase (AChE) in vitro, obtain-
ing thus the first known successful reactivation of the 
previously irreversibly phosphorylated AChE (2).
In 1955 oximes were discovered as specific antidotes, 
being much more efficient than hydroxylamine (3, 4). 
Actually, pralidoxime (PAM-2), the first tested oxime, 
could reactivate the phosphorylated enzyme about a 
million times faster than hydroxylamine (5).
In the same year it was established that the 
enzyme did not remain susceptible to reactivation by 
the oximes forever – the enzyme-inhibitor complex 
could undergo an “ageing” reaction depending on 
the chemical structure of inhibitor (6). In 1959, the 
experiments on diisopropylfluorophosphate (DFP)-
inhibited butyrylcholinesterase (BuChE)  showed 
that the mechanism underlying this “ageing” process 
consisted of dealkylation of the OPC residue (7).
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Soman is a nerve agent notorious for its rapid 
“ageing” properties; the half-time of this process is only 
2.3 min in bovine erythrocyte AChE at 37 ºC and pH 
7.35. Soman, in turn, has a branched and voluminous 
pinacolyl leaving group (Figure 1), rendering thus the 
nucleophilic attack by the oximes impossible (8). It was 
later confirmed that the “ageing” process is fastest 
after poisoning of rats with soman (half-time 4 min) 
and significantly slower after poisoning with the other 
three major nerve agents sarin (12 h), tabun (46 h) 
and VX (12 days) (9).
MECHANISM OF ACTION OF OXIMES
Oximes can bind reversibly to the AChE molecule 
either at its catalytic site (active centre), allosteric 
(peripheral) site or at both sites of the enzyme; 
binding to either site affects the catalytic properties 
of the AChE (cf. 11). Every oxime has a strong 
positive charge in its molecule that navigates it to the 
negatively charged anionic site at the active centre of 
AChE, attracting thus the oxime molecule closer to 
the molecule of the OP residuum (cf. 5). Thereafter, 
the oxime group performs the so-called nucleophilic 
attack at the phosphorus atom of the OP residuum, 
which results in the formation of an unstable enzyme-
inhibitor-oxime complex. The ultimate result is the 
splitting of the complex into a phosphorylated oxime 
and reactivated enzyme (Figure 2).
CONTEMPORARY OXIMES
Among the many classes of oximes investigated so 
far, those that found clinical application can be divided 
into the monopyridinium and bispyridinium ones. The 
only currently used monopyridinium oxime is PAM-2, 
while the most significant bispyridinium oximes are 
trimedoxime (TMB-4), obidoxime (LüH-6, Toxogonin), 
HI-6, and HLö-7 (Figure 3) (12).
Pralidoxime (PAM-2)
Pralidoxime (pyridinium-2-aldoxime) was 
synthesised in the USA in 1955 (13). Its four salts, 
chloride (PAM-2 Cl), methiodide, methysulphate and 
mesylate (P2S), were investigated and introduced 
into practice (5). PAM-2 is very efficient in reactivating 
AChE inhibited with sarin or VX (14-19), but is not with 
tabun or soman (20-22).
As a quaternary pyridinium salt, PAM-2 does not 
readily penetrate the blood-brain barrier (BBB), and 
this is why pro-2-PAM was synthesised as a pro-drug 
of PAM-2 that can gain access to the central nervous 
system (CNS). Unexpectedly, it turned out to be 
even less effective than PAM-2 against experimental 
poisoning with paraoxon (23). However, it appears 
that in OPC poisoning PAM-2 can pass BBB at higher 
concentrations when given with atropine.
Trimedoxime (TMB-4)
Chemically, TMB-4 Cl2 is a 1,3-bis(4-hydroxyim-
minomethyl-1-pyridinio)propane-dichloride and was 
synthesised in the USA in 1957 (24) and patent-pro-
tected in 1967 (25). It is the only of the major bispy-
ridinium oximes with a propylene bridge between the 
two pyridinium rings. Experiments have shown that 
TMB-4 is a more potent reactivator of the DFP-inhib-
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Figure 1 Chemical structure of nerve agents and their acute toxicity 
after subcutaneous administration in rats (according to ref. 
no. 10)
Figure 2 Reactivation of phosphorylated acetylcholinesterase with 
pralidoxime and formation of reactivated enzyme and 
phosphorylated oxime
Figure 3 Chemical structure of pyridinium oximes used in the treatment 
of OPC poisoning. X stands for an anion
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ited AChE than PAM-2 (26) and by 15 % to 40 % better 
reactivator than LüH-6 in case of tabun inhibition (27). 
TMB-4 was also the first oxime that was efficient in the 
treatment of animals intoxicated with tabun (28-30). 
It can also protect animals poisoned with sarin or VX, 
but not those poisoned with soman (29, 31). At the 
same time, TMB-4 is the most toxic oxime among the 
“great four”; it was shown in mice that its median lethal 
dose (LD50) is 3, 4 and 8 times lower than respective 
LD50 of LüH-6, PAM-2 and HI-6 (32).
Obidoxime (LüH-6, Toxogonin)
Chemica l ly,  LüH-6 Cl 2 i s  a  [1 ,3-b is (4-
hydroxyimminomethyl-1-pyridinio)-2-oxapropane] 
dichloride. It was named in honour of A. Lüttringhaus 
and I. Hagedorn who synthesised it in Germany 
and introduced into medical practice in 1964 (33). 
The new oxime immediately showed a significant 
potential as antidote in OPC poisoning (34). Being 
a good AChE reactivator, LüH-6, administered in 
vivo with atropine, efficiently protected experimental 
animals against poisoning with tabun (20, 35), sarin 
(20, 35) and VX (35). LüH-6 was somewhat more 
efficient than TMB-4 as antidote against tabun 
poisoning (36). Nevertheless, like PAM-2 and TMB-
4, LüH-6 was inefficient against soman poisoning 
in mice (29), guinea-pigs (20) and primates (37). In 
contrast to TMB-4, when administered with atropine 
in pyridostigmine-pretreated guinea-pigs, LüH-6 can 
give some protection against soman, as well (20). 
Although less toxic than TMB-4, this oxime can show 
its hepatotoxic potential (5, 38).
HI-6
The first oxime that could reactivate soman-
inhibited AChE and provide at least some protection of 
animals experimentally poisoned with this nerve agent. 
It was synthesised in 1966 and given the code name 
HS-6, after the last name initials of Ilse Hagedorn and 
Klaus Schoene (39). Shortly thereafter its congener 
was launched; an oxime named HI-6 after the initials 
of the last name of Ilse Hagedorn and the first name 
of her student Irmo Stark, chemists who synthesised 
it in Freiburg, Germany in 1966 (9, 40). It was shown 
that HI-6 was more potent than LüH-6 and HS-6 in 
protecting various rodent species from poisoning with 
soman (17, 20, 41), as well as sarin and especially VX 
(17, 20, 29). The only drawback of HI-6 was that this 
oxime could not reactivate tabun-inhibited AChE (42, 
43). As a consequence, it was proven to be inefficient 
when used alone against tabun poisoning (17, 20, 
29). Nevertheless, in some other studies HI-6 showed 
a similar degree of protection against tabun and 
soman poisoning in primates (37), while sufficiently 
high doses of the oxime could even protect rats from 
multiple lethal doses of tabun (44). The toxicity of HI-6 
is low, actually the lowest among the aforementioned 
oximes (29, 32, 45), with the LD50 in rats as high as 
781.3 mg kg-1 or 2071 mol kg-1 (12).
HLö-7
The fourth and the last important “Hagedorn 
oxime” (after LüH-6, HS-6 and HI-6) is HLö-7, 
named after Ilse Hagedorn and Marianne Löffler and 
also synthesised in Freiburg, Germany in 1986 (46). 
Chemically, this oxime is a 1-[[[4-(aminocarbonyl)pyri
dinio]methoxy]methyl]-2,4-bis[(hydroxyimino)methyl]
pyridinium-diiodide. The new oxime reactivates AChE 
inhibited by any of the four major nerve agents (47-
50), as well as the enzyme inhibited by cyclosarin (51). 
In addition, HLö-7 is more efficien than PAM-2, LüH-6 
and HI-6 in restoring neuromuscular transmission 
impaired by in vitro superfusion of the neuro-muscular 
preparation with tabun, sarin, soman or cyclosarin 
(52). It was found that HLö-7 induced a significant 
reactivation of AChE in mice diaphragms previously 
inhibited with tabun, sarin, soman and cyclosarin 
(53). Although both HI-6 and HLö-7 can antagonise 
sarin-induced hypothermia (proving thus that they, 
when given with atropine, can pass the BBB and 
gain access to the CNS) (53, 54), the LD50 of HLö-7 
is 2.5 times lower than of HI-6, which means that 
the new oxime is more toxic (53). The cardiovascular 
tolerability of HLö-7 was similar, but not as good as 
that of HI-6, at least in anaesthetised guinea-pigs 
(55). On the scale of efficacy, HLö-7 turned out to be 
somewhat more effective than HI-6 against tabun and 
VX poisoning and less effective against sarin, soman, 
and cyclosarin poisoning (51, 56). In guinea-pigs, a 
species considered the closest model to the primates 
in OPC poisoning, HLö-7-induced protection against 
tabun poisoning was significantly better than that of 
HI-6, while HI-6 was only slightly more efficient than 
HLö-7 in soman poisoning (57).
OXIME SELECTION CRITERIA
The main criteria to be used when choosing the 
best oxime against the four classical nerve agents 
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tabun, sarin, soman and VX, as well as cyclosarin, 
used by the former Iraqi regime (51) are:
A) ability to reactivate AChE inhibited by nerve 
agents in vitro and in vivo,
B) when given with atropine, ability to assure 
survival of experimental animals, poisoned with 
multiple lethal doses of nerve agents,
C) when given with atropine, ability to pass the 
BBB and reach the CNS in significant and 
therapeutically relevant concentrations,
D) ability to express some “direct pharmacological 
effects” such as influence on the liberation of 
acetylcholine from pre-synaptic nerve endings 
(58),
E) the oxime’s own toxicity itself,
F) chemical and pharmaceutical stability of the 
oxime and
G) suitability for formulating the oxime in the form 
of auto-injector.
According to these criteria,
A) Only HLö-7 can reactivate AChE inhibited by 
all the nerve agents mentioned in vitro and in
vivo. Follows HI-6, which cannot reactivate only 
tabun-inhibited AChE.
B) When administered with atropine, both HI-
6 and HLö-7 can assure in vivo protection 
against multiple LD50s of all five nerve agents, 
with HI-6 being more efficient with sarin, soman 
and cyclosarin and less efficient with tabun and 
VX. These differences seem not to be of clinical 
importance.
C) Although without carbamate pre-treatment 
none of the oximes studied in animals can 
induce a significant reactivation of brain 
AChE inhibited by soman, the fact that only 
HI-6 and HLö-7 can reactivate the brain 
AChE inhibited by sarin and antagonise sarin-
induced central hypothermia, proves the 
ability of these two oximes to reach the brain 
at concentrations relevant to exert their central 
antidotal effects.
D) All of the oximes have some of the so-called 
“direct pharmacological (or non-AChE-
reactivating) effects”. However, it seems that 
HI-6 and especially HLö-7 have some pre-
junctional properties that decrease the amount 
of acetylcholine released into the synaptic cleft, 
an effect so beneficial under the conditions of 
AChE inhibition by soman (58). 
E) Among the five current oximes, HI-6 is by far 
the least toxic, followed by HLö-7, PAM-2, 
LüH-6 and TMB-4. A clinical study with HI-6 
administered at doses up to 500 mg in 22 
healthy volunteers revealed no adverse effects 
(59).
F) While older oximes PAM-2, TMB-4 and LüH-
6 are stable in water solutions and can be 
prepared in ampoules, HI-6 and HLö-7 are not 
and therefore should be kept as powder over a 
longer time and dissolved immediately before 
use.
G) Both HI-6 and HLö-7 were successfully 
prepared in the form of wet-dry auto-injector. 
Similar devices containing PAM-2, TMB-4 and 
LüH-6 also exist, but in the form of solution 
with atropine (60).
MODERN AUTO-INJECTORS
Based on various doctrines, every country had its 
rationale while developing auto-injectors to protect 
their armed forces. Table 1 contains some of the 
solutions of eight countries, mostly belonging to 
NATO (61).
Table 1 Prophylactic and treatment doctrines/auto-injector content in some countries (according to ref. no. 61)
Country Prophylaxis* Anticholinergic Oxime Anticonvulsant
United Kingdom pyridostigmine atropine P2S avizafone
United States pyridostigmine atropine PAM-2Cl diazepam
Germany pyridostigmine atropine LüH-6 -
Finland pyridostigmine atropine LüH-6 -
Norway pyridostigmine atropine LüH-6 diazepam
The Netherlands pyridostigmine atropine LüH-6 avizafone
Sweden pyridostigmine atropine HI-6 -
Canada pyridostigmine atropine HI-6 diazepam
*Pyridostigmine pre-treatment is administered per os, one 30-mg-tablet every 8 hours 
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It is evident that all these armies favour the use 
of pyridostigmine as a pre-treatment antidote and 
atropine as classical antimuscarinic drug. They also 
have an oxime as a part of the antidotal combination, 
but the choice of the oxime varies a lot - from 
pralidoxime salts in the UK and the US to LüH-6 in 
Norway, Finland, Germany and The Netherlands and 
HI-6 in Sweden and Canada.
Due to significant costs, only a few of these 
countries provide anticonvulsants in the form of auto-
injector. The greatest advantage of avizafone over 
diazepam is water solubility, which allows its presence 
in aqueous solutions of atropine as the “wet” part of 
the “wet-dry” autoinjectors (with HI-6 powder being 
the dry part).
CANADIAN HI-6 INITIATIVE
Various world armies have auto-injectors against 
nerve agents that contain atropine and one of the four 
classical oximes. The drawbacks of the current HI-6-
based solutions include: (a) The lack of a commercial 
source of supply of Good Manufacturing Practice 
(GMP)-grade HI-6, (b) a cumbersome system of 
multiple auto-injectors and (c) an incomplete data 
package to support a regulatory submission (missing 
of the HI-6 Drug Master File) (62).
In order to provide the auto-injector with the 
best and most potent AChE reactivator, the Defence 
Research and Development Canada (DRDC) 
received in the 1990s a core funding from the federal 
government’s CBRN Research and Technology 
Initiative (CRTI). DRDC will receive financial and 
scientific assistance through a six-nation collaboration 
(between Canada, Germany, the Netherlands, Norway, 
Sweden and the United Kingdom). Its ultimate result 
should be three products: (1) 3-in-1 auto-injector 
(atropine, HI-6 dimethanesulphonate and avizafone, 
as anticonvulsant), (2) 2-in-1 auto-injector (atropine 
and HI-6 dimethanesulphonate) and (3) HI-6 in a vial 
for administration by medically trained personnel.
In a recent study performed in anaesthetised pigs, 
HI-6 dimethanesulphonate was shown to have the 
same pharmacokinetic properties as the original HI-
6 dichloride salt. In the same study, both HI-6 salts, 
administered with atropine, successfully protected 
guinea-pigs from poisoning against a fivefold LD50 of 
soman or cyclosarin (63).
This project continues to progress under a trilateral 
Memorandum of Understanding, signed by the 
governments of Canada, the United Kingdom and 
the Netherlands (62).
This initiative suggests that HI-6 has won the tight 
race with HLö-7 for the title of the best causal antidote 
against nerve agent poisoning. Even though HLö-7 
has a few advantages over HI-6, it is quite obvious 
that in combination with atropine both oximes are 
superior to TMB-4, LüH-6 and especially to PAM-2 in 
the treatment of nerve agent poisoning.
Note that clinical experience with PAM-2 iodide 
used in combination with atropine and diazepam in 
the treatment of the Tokyo underground sarin attack 
victims in 1995 was highly favourable (64). This, 
however, does not mean that this oxime should be 
the drug of choice in the treatment of nerve agent 
poisonings, because it is less efficient against tabun 
and soman (65).
ORGANOPHOSPHORUS INSECTICIDES
Poisoning with OP insecticides (OPIs) yielded quite 
the opposite results. The worst were obtained with HI-
6 and HLö-7 and, to some extent, with PAM-2, while 
the most efficient oximes were TMB-4 and LüH-6 (66, 
67). Jokanoviþ and Maksimoviþ (66) studied acute oral 
toxicity of 26 OP insecticides in rats and the efficacy 
of antidotal treatment involving TMB-4, LüH-6, PAM-
2 and HI-6 (given with atropine and diazepam) in 
animals dosed with 2 LD50s of the insecticides. The 
success of the therapy depended on the chemical 
structure of OPC. The oximes were potent antidotes 
against insecticides having the phosphate structure, 
and provided some protection against phosphonates, 
phosphorothiolates, phosphorothionates, and 
phosphorodithioates. However, none of them were 
effective against dimethoate and pyridafenthion. 
TMB-4 turned out to be the most effective oxime 
in the treatment of OP insecticide poisoning. In 
addition, AChE inhibited with OP insecticides, having 
mainly dimethyl and diethyl phosphate structure, can 
spontaneously reactivate with half-times for dimethyl 
phosphates of 1.3 h in vitro and 2.1 h in vivo. The rate 
of spontaneous reactivation for diethyl phosphates 
bound to AChE is about ten times slower (68).
Although the only two randomised controlled 
clinical trials performed so far did not result in a final 
proof of the efficacy of oximes in the treatment of 
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OPI poisonings in humans (69), our experimental and 
clinical experience suggests that, among the oximes 
mentioned, only TMB-4 and LüH-6, relatively toxic 
themselves, can provide reactivation and antidotal 
protection against most OPIs.
When it comes to an ultimate choice of an oxime 
for this indication, it seems that
somewhat better tolerability and the existence of 
auto-injectors with atropine speak in favour of LüH-6 
over TMB-4.
CONCLUSION
There is no universal oxime, capable of protecting 
against all the known OPCs. In military toxicology, 
HI-6 methansulphonate seems to be the best choice 
for nerve agent poisoning, and should make part of 
the wet-dry auto-injector with atropine and avizafone. 
On the other hand, LüH-6 dichloride, in ampoules or 
in auto-injectors, seems to be the best choice for the 
treatment of OPI poisoning. The best alternatives for 
the proposed solutions would be HLö-7 and TMB-4, 
respectively.
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Sažetak
PIRIDINIJEVI OKSIMI: RAZLOZI ZA NJIHOV ODABIR KAO KAUZALNIH ANTIDOTA PROTIV 
OTROVANJA ORGANOFOSFATIMA I SADAŠNJA RJEŠENJA ZA AUTOINJEKTORE
Tijekom proteklih pet desetljeþa, za pet piridinijevih oksima ustanovljeno je da zavreāuju da budu 
upotrijebljeni kod ljudi kao antidoti protiv živĀanih bojnih otrova: pralidoksim, u obliku klorida, PAM-2 Cl 
ili mesilat, P2S (protiv sarina, ciklosarina i VX-otrova), trimedoksim ili TMB-4 i obidoksim ili LüH-6 (oba 
protiv tabuna, sarin i VX-otrova), HI-6 (protiv sarina, somana, ciklosarina i VX-otrova) i HLö-7 (protiv svih 
pet živĀanih bojnih otrova).
Radi osiguranja autoinjektora s najboljim i najpotentnijim reaktivatorom acetilkolinesteraze, Kanadska 
uprava za obrambena istraživanja i razvoj (DRDC) primila je tijekom 1990-ih godina osnovnu financijsku 
potporu od IstraživaĀke i tehnološke inicijative u oblasti kemijske, biološke, radiološke i nuklearne zaštite 
(CRTI) Vlade Kanade. DRDC þe primati financijsku i znanstvenu pomoþ suradnjom šest zemalja (izmeāu
Kanade, NjemaĀke, Nizozemske, Norveške, Švedske i Velike Britanije). Njezin bi krajnji rezultat trebala biti 
tri proizvoda: (1) “3-u-1” autoinjektor (atropin, HI-6 dimetansulfonat i avizafon, kao antikonvulzant), (2) 
“2-u-1” autoinjektor (atropin i HI-6 dimetansulfonat) i (3) HI-6 dimetansulfonat u boĀici za primjenu od 
medicinski obrazovanog osoblja.
Prethodna eksperimentalna i kliniĀka iskustva sugeriraju da, meāu spomenutim oksimima, jedino 
trimedoksim i obidoksim, koji su relativno toksiĀni per se, mogu osigurati reaktivaciju acetilkolinesteraze 
i antidotsku zaštitu protiv veþine organofosfornih insekticida.
Potraga za “omnipotentnim” oksimom, djelotvornim i protiv svih živĀanih bojnih otrova i protiv svih 
organofosfornih insekticida, još je u toku.
KLJUÿNE RIJEÿI: acetilkolinesteraza, organofosforni spojevi, reaktivacija, živĀani bojni otrovi 
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